Shabir Ganai

Dr. Shabir Ganai


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2016 in Current Neuropharmacology
Verified
Journal Article
Open access
SGShabir Ganai
Shabir Ganai
MRMahalakshmi Ramadoss
Mahalakshmi Ramadoss
VMVijayalakshmi Mahadevan
Vijayalakshmi Mahadevan
Epigenetic regulation of neuronal signalling through histone acetylation dictates transcription programs that govern neuronal memory, plasticity and learning paradigms. Histone Acetyl Transferases (HATs) and Histone Deacetylases (HDACs) are antagonistic enzymes that regulate gene expression through acetylation and deacetylation of histone proteins around which DNA is wrapped inside a eukaryotic cell nucleus. The epigenetic control of HDACs and the cellular imbalance between HATs and HDACs dictate disease states and have been implicated in muscular dystrophy, loss of memory, neurodegeneration and autistic disorders. Altering gene expression profiles through inhibition of HDACs is now emerging as a powerful technique in therapy. This review presents evolving applications of HDAC inhibitors as potential drugs in neurological research and therapy. Mechanisms that govern their expression profiles in neuronal signalling, plasticity and learning will be covered. Promising and exciting possibilities of HDAC inhibitors in memory formation, fear conditioning, ischemic stroke and neural regeneration have been detailed.

13 February 2021 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
SGShabir Ganai
Shabir Ganai
FSFarooq Ahmad Sheikh
Farooq Ahmad Sheikh
ZBZahoor Ahmad Baba
Zahoor Ahmad Baba
MMMudasir Ahmad Mir
Mudasir Ahmad Mir
MMMohd Ayoob Mantoo
Mohd Ayoob Mantoo
MYManzoor Ahmad Yatoo
Manzoor Ahmad Yatoo

1 October 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SGShabir Ganai
Shabir Ganai
SBShahid Banday
Shahid Banday
ZFZeenat Farooq
Zeenat Farooq
ABAltaf Bhat
Altaf Bhat


1 March 2020 in Saudi Journal of Biological Sciences
Verified
Journal Article
Open access
MMMudasir A. Mir
Mudasir A. Mir
SGShabir Ganai
Shabir Ganai
Sheikh MansoorSheikh Mansoor
Sheikh Mansoor
SJSumira Jan
Sumira Jan
PMP. Mani
P. Mani
PAParvaiz Ahmad
Parvaiz Ahmad
Saffron plant (Crocus sativus L.) is being used as a source of saffron spice and medicine to cure or prevent different types of diseases including cancers. We report the isolation, characterization of bioactive small molecule ([crocetin (β-d-glucosyl) ester] from the leaf biowastes of saffron plant of Kashmir, India. MTTC assay and Bio-autography aided approach were used to assess anti-oxidant activity and anti-cancer properties of crocin (s) against DPPH free radical and breast cancer cell line respectively. Crocetin beta-d-glucosyl ester restrained proliferation of human breast adeno-carcinoma cell model (MCF-7) without significantly affecting normal cell line (L-6). Further studies involving molecular mechanics generalized born surface area and molecular docking showed that crocetin beta-d-glucosyl ester exhibits strong affinity for estrogen receptor alpha and histone deacetylase 2 (crucial receptors involved in breast cancer signalling) as evidenced by the negative docking score and binding free energy (BFE) values. Therefore, crocetin beta-d-glucosyl ester from Crocus sativus biowastes showed antiproliferative effect possibly by inhibiting estrogen receptor alpha and HDAC2 mediated signalling cascade.

11 July 2018 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
SGShabir Ganai
Shabir Ganai
ZFZeenat Farooq
Zeenat Farooq
SBShahid Banday
Shahid Banday
ABAltaf Bhat
Altaf Bhat
Aim: Aberrant activity of class I histone deacetylases (HDACs) has strong implications for various cancers. Targeting these HDACs with synthetic HDAC inhibitors has shown significant side effects such as atrial fibrillation and QT prolongation emphasizing the need of natural inhibitors as substitutes to synthetic ones. Results: The binding propensity of the two plant-derived inhibitors apigenin and luteolin towards class I HDAC isoforms was checked using extra-precision molecular docking and implicit solvation MMGBSA. Apigenin showed a superior binding affinity against these isoforms as compared to luteolin. Both inhibitors docked stable to the binding pocket of these HDACs as determined by molecular dynamics simulation study. Conclusion: Apigenin and luteolin may serve as substitutes to synthetic inhibitors for effective HDAC based anticancer therapy.